ONCOMYX THERAPEUTICS
OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach which can be carried systemically by human leukocytes where it can then infect tumor cells. The company was founded in 2018 and is headquartered in Phoenix, Arizona.
ONCOMYX THERAPEUTICS
Industry:
Biotechnology Health Diagnostics Medical Therapeutics
Founded:
2018-01-01
Address:
Phoenix, Arizona, United States
Country:
United States
Website Url:
http://www.oncomyx.com
Total Employee:
11+
Status:
Active
Total Funding:
50 M USD
Current Advisors List
Investors List
Delos Capital
Delos Capital investment in Series B - OncoMyx Therapeutics
Madison Partners
Madison Partners investment in Series B - OncoMyx Therapeutics
Xeraya Capital
Xeraya Capital investment in Series B - OncoMyx Therapeutics
City Hill Ventures
City Hill Ventures investment in Series B - OncoMyx Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - OncoMyx Therapeutics
Lumira Ventures
Lumira Ventures investment in Series B - OncoMyx Therapeutics
B Capital Group
B Capital Group investment in Series B - OncoMyx Therapeutics
Korea Investment Partners
Korea Investment Partners investment in Series B - OncoMyx Therapeutics
LYZZ Capital
LYZZ Capital investment in Series B - OncoMyx Therapeutics
Official Site Inspections
http://www.oncomyx.com Semrush global rank: 4.39 M Semrush visits lastest month: 2.55 K
- Host name: 202.88.225.35.bc.googleusercontent.com
- IP address: 35.225.88.202
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "OncoMyx Therapeutics"
OncoMyx Therapeutics - Crunchbase Company Profile & Funding
OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets …See details»
OncoMyx Therapeutics Company Profile 2024: Valuation, Funding ...
OncoMyx Therapeutics General Information Description. Developer of oncolytic immunotherapies designed to assist in creating an immune response and treat cancer. The company's virus and …See details»
OncoMyx Therapeutics - LinkedIn
OncoMyx Therapeutics | 1,587 followers on LinkedIn. We are developing myxoma virotherapies to expand the effectiveness of immunotherapies in the treatment of cancer. | OncoMyx …See details»
Lumira Co-Leads OncoMyx $50 Million Series B to ... - Lumira …
Dec 8, 2021 OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B …See details»
Phoenix Bioscience Startup That Delivers Lifesaving Medicines for ...
Dec 8, 2021 OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B …See details»
ASU spinout OncoMyx Therapeutics, Skysong Innovations …
Feb 26, 2020 OncoMyx Therapeutics, an Arizona State University spinout and privately-held oncolytic immunotherapy company founded on the myxoma virus (MYXV) platform, has …See details»
OncoMyx Therapeutics invests in bringing cancer treatments to …
Jun 6, 2019 OncoMyx plans to use the proceeds of the $25 million investment to advance development of its lead oncolytic virus therapeutic program and advance additional programs …See details»
OncoMyx closes $50M Series B to advance cancer-killing payload …
Dec 10, 2021 Phoenix-based OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by …See details»
Arizona State spin-off OncoMyx Therapeutics raises $25 million to ...
Jun 15, 2019 OncoMyx Therapeutics has raised $25 million in series A financing to develop and test oncolytic viruses alongside cancer immunotherapies. OncoMyx was cofounded by Arizona …See details»
OncoMyx nabs $50M to jump into the clinic with its rabbit pox …
Dec 8, 2021 In April, startup OncoMyx published some very early preclinical models showing its engineered rabbit pox virus could help against lung cancer; now, it's got off a $50 million …See details»
Oncomyx takes oncolytic virus tech into clinic with $50M
Dec 8, 2021 Oncomyx takes oncolytic virus tech into clinic with $50M series B funding. Dec. 8, 2021. By Richard Staines. No Comments. It’s been more than six years since the FDA’s first …See details»
OncoMyx Presents at AACR First Data Showing Multi-Armed …
Apr 10, 2021 OncoMyx has specifically built multi-armed myxoma viruses with immunomodulatory proteins and payloads designed to stimulate anti-tumor immunity and …See details»
OncoMyx Closes $50 Million Series B to Advance a Novel Immuno …
Dec 8, 2021 PHOENIX--(BUSINESS WIRE)--OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, …See details»
OncoMyx Presents New Data at AACR 2022 Demonstrating
Apr 8, 2022 “OncoMyx’s myxoma virus is the first large, multi-armed oncolytic virus to demonstrate efficacy in preclinical models of multiple myeloma,” said Steve Potts, Ph.D., MBA, …See details»
OncoMyx Announces Presentation of Preclinical Efficacy Data of …
Nov 9, 2020 PHOENIX--(BUSINESS WIRE)--OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced the presentation of preclinical data at the Society for …See details»
AACR: OncoMyx's engineered rabbit pox virus shows promise in …
Apr 12, 2021 OncoMyx tested the drug in immunodeficient mice bearing human NSCLC cells. The multi-armed viral therapy slowed tumor growth better than control or unedited myxoma …See details»
OncoMyx Closes $50 Million Series B to Advance a Novel
Dec 8, 2021 “OncoMyx builds on more than three decades of research into the myxoma virus, brings together the top team with experience developing targeted cancer treatments, …See details»
OncoMyx lands $50m Series B led by Lumira, B Capital
Dec 13, 2021 OncoMyx Therapeutics is advancing multi-armed, systemic immunotherapies with the potential to be broadly effective in treating solid tumors and heme cancers. Successful …See details»
OncoMyx Presents New Data at SITC 2021 Demonstrating
Nov 12, 2021 OncoMyx Presents New Data at SITC 2021 Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Solid Tumors and Heme …See details»
Lumira Co-Leads OncoMyx $50 Million Series B to Advance a …
Dec 8, 2021 OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B …See details»